Comparison of METHOHEXITAL (cas 18652-93-2) and etomidate as anesthetic agents for electroconvulsive therapy in affective and psychotic disorders

Add time:09/26/2019    Source:sciencedirect.com

BackgroundECT is a well-established treatment for severe depression. The available data on psychosis are limited, but reliable. Its therapeutic potential relies on the induction of a generalized seizure. Besides other narcotics, METHOHEXITAL (cas 18652-93-2) and etomidate are used for general anesthesia in ECT. Since prolonged seizures have been reported following the use of etomidate, it can be deduced that the substances might differ in their anticonvulsant properties, resulting in a lower increase in stimulus intensity during the course of treatment under etomidate. Besides this hypothesis, we aimed to investigate the differential effects of etomidate and methohexital on clinical features, ECT parameters and side effects of the treatment.

We also recommend Trading Suppliers and Manufacturers of METHOHEXITAL (cas 18652-93-2). Pls Click Website Link as below: cas 18652-93-2 suppliers

Prev:Original ContributionEvaluation of METHOHEXITAL (cas 18652-93-2) as an alternative to propofol in a high volume outpatient pediatric sedation service
Next:Short communicationLanguage assessment in Wada test: Comparison of METHOHEXITAL (cas 18652-93-2) and amobarbital)